Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04643418RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors you can’t remove
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
TaipeiAges 18 years+ - NCT05477849RecruitingPhase 1
Study drug for people with advanced solid tumors
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
Hangzhou, ZhejiangAges 18–75 - NCT05405595RecruitingPhase 1/Phase 2
Study drug with pembrolizumab for advanced solid tumors
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT04387916RecruitingPhase 1
Test drug KC1036 in people with advanced solid tumors
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT05547321RecruitingPhase 1
New cancer drug plus immunotherapy for advanced solid tumors
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
Boston, MassachusettsAges 18 years+ - NCT04093466RecruitingPhase 1
Testing a new pill for advanced solid tumors
This Phase 1 trial tests kanitinib (CX1003), a new cancer medicine, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The goal is to find a safe dose and see early signs of tumor response.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04685226RecruitingPhase 1/Phase 2
Testing ICP-723 for advanced solid tumors you can’t remove
This trial studies ICP-723 (a new medicine) in people with advanced cancers that cannot be removed with surgery, and in some primary brain (CNS) tumors. It’s an early-phase study (Phase 1/2) to see how the treatment works and how safe it is.
Hefei, AnhuiAges 12 years+ - NCT04282031RecruitingPhase 1/Phase 2
BPI-1178 for advanced breast cancer or solid tumors
This early-phase study tests BPI-1178 in people with advanced (stage 4 or hard-to-treat) solid tumors, including HR+/HER2- breast cancer. It looks at how well the treatment works and how safe it is, especially after standard treatments have stopped working or aren’t an option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04219254RecruitingPhase 1/Phase 2
Testing BI-1206 with pembrolizumab for advanced solid cancers
This early-phase trial studies BI-1206 together with pembrolizumab to treat advanced solid tumors. It may be an option if your cancer has progressed after prior anti–PD-1/PD-L1 treatment (or, in some groups, if standard treatments aren’t suitable).
Los Angeles, CaliforniaAges 18 years+ - NCT05067283RecruitingPhase 1
Study of Calderasib for KRAS G12C advanced cancers
This trial tests a new drug, Calderasib, for people with advanced solid tumors that have a specific mutation called KRAS G12C. It may help if your cancer has not responded to previous treatments or if you have certain types of lung or colorectal cancer.
Tampa, FloridaAges 18 years+ - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Orange, CaliforniaAges 18 years+ - NCT06962254RecruitingPhase 1
Imatinib and Trametinib for KRAS-mutated solid tumors
This trial tests a combination of two targeted drugs, imatinib and trametinib, for people with advanced solid tumors that have a specific KRAS mutation (G12X). It may be an option if standard treatments have stopped working or are not available.
Taichung, TaichungAges 20 years+ - NCT07671534RecruitingPhase 2
Metronomic chemotherapy with gemcitabine, mitomycin C, and thalidomide for advanced solid tumors
This trial tests a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in a low, frequent 'metronomic' schedule to treat advanced solid tumors that have already been treated. The goal is to see if this approach can slow or stop tumor growth with fewer side effects.
Santa Monica, CaliforniaAges 18 years+ - NCT06257680RecruitingPhase 1
ReT01 cell therapy for advanced solid tumors
This trial tests a new cell therapy called ReT01 for people with advanced solid tumors that have stopped responding to standard treatments. It uses your own immune cells from a tumor sample to fight the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06167317RecruitingPhase 1
Study of GS-0201 alone and combined for advanced solid tumors
This trial tests a new drug called GS-0201, either by itself or with other treatments, for people with advanced solid tumors. The goal is to see if it is safe and helpful.
Boston, MassachusettsAges 18 years+ - NCT05701709RecruitingPhase 1
First-in-human test for a new drug in advanced solid cancers
This Phase 1 study tests SHR-A2102, a new cancer medicine, in adults with advanced solid tumors. It mainly looks at safety and how the body handles the drug, and it may help if standard treatments are not working or are not an option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07141706RecruitingPhase 1
Testing DB-1317 in advanced solid tumors
This trial tests an investigational drug (DB-1317) that targets a protein called ADAM9, found on some solid tumors. It is for people with advanced cancers that have not responded to other treatments, and aims to see if the drug is safe and works.
Los Angeles, CaliforniaAges 18 years+ - NCT05801237RecruitingPhase 1/Phase 2
Study of two drugs for advanced solid tumors
This Phase 1/2 study tests two investigational medicines (PE0116 and PE0105) in people with advanced solid cancers that have spread or cannot be removed by surgery. It may help shrink tumors or slow disease when standard treatments have not worked or are not tolerated.
ShanghaiAges 18–75 - NCT07126665RecruitingPhase 1/Phase 2
Study of MHB088C plus MHB039A for advanced solid tumors
This trial tests a combination of two experimental drugs, MHB088C and MHB039A, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07161414RecruitingPhase 1
Study of rilvegostomig for advanced solid tumors
This trial tests an experimental drug called rilvegostomig, given as a shot under the skin, for people with advanced solid tumors that have spread or can't be removed and have already had standard treatments. The study checks how the body processes the drug and its safety.
Huntersville, North CarolinaAges 18 years+ - NCT07128303RecruitingPhase 1
GS-5319 for adults with solid tumors lacking MTAP
This trial tests an investigational drug called GS-5319 in people with solid tumors that are missing a protein called MTAP. It is for those whose cancer has continued to grow after other treatments or who cannot have standard therapy.
Boston, MassachusettsAges 18 years+ - NCT06240546RecruitingPhase 1
Study of LPM6690176 for advanced solid tumors
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
BeijingAges 18–75 - NCT04469530RecruitingPhase 2
Sirolimus plus low-dose chemotherapy for high-risk childhood tumors
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
Atlanta, GeorgiaAges 1–30 - NCT06417554RecruitingPhase 1/Phase 2
Study of SHR-A2102 with or without other cancer drugs for advanced solid tumors
This trial tests a new drug, SHR-A2102, given alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy or for those who have not yet received systemic treatment. The goal is to see if it can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,355 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.